Bayerische Motoren Werke ADR (BMWYY)

TransCode Therapeutics (NASDAQ: RNAZ) announced completion of its Phase 1a clinical trial of TTX-MC138, an investigational inhibitor of microRNA-10b, achieving its primary safety endpoint and establishing a recommended Phase 2 dose. Sixteen patients were treated with no significant safety events or dose-limiting toxicities observed, and 44% achieved stable disease lasting four months or longer. The favorable safety, durability, and pharmacodynamic data support advancing TTX-MC138 into a Phase 2a trial to further assess efficacy across multiple metastatic cancer indications.

NextPlat (NASDAQ: NXPL, NXPLW), a global consumer products and services company providing healthcare and technology solutions through e-commerce and retail channels, announced the promotion of Amanda L. Ferrio to Chief Financial Officer, succeeding Cecile Munnik, CPA/CA, following a transition period through the company’s Q3 2025 filing. Ferrio, who has over 15 years of accounting and finance experience, previously served as Vice President of Accounting & Finance at Progressive Care LLC, where she led financial reporting, budgeting, and SEC compliance. CEO David Phipps said her deep operational insight will support NextPlat’s focus on financial performance and sustainable shareholder value.

There is general agreement that the U.S. health care system has issues, but there isn’t consensus on what exactly needs to be done to fix those issues. A new report published by Trilliant Health, an economic analysis company, points out some notable trends that should be given the attention they deserve by health care system stakeholders.

Soligenix (NASDAQ: SNGX) recently announced the closing of a $7.5 million public offering, providing the company with additional capital to advance its pipeline ( https://ibn.fm/tCsub ). This funding extends Soligenix’s cash runway through the end of 2026, ensuring that the company has the financial resources to reach key inflection points across its portfolio, including late-stage clinical trials and regulatory milestones. The move underscores Soligenix’s commitment to advancing therapies for rare diseases where there is significant unmet medical need.

Derrimut VIC () October 12, 2025 -- The leading motorcycle dismantling service launches worldwide shipping while expanding domestic operations to meet rising demand for quality used parts.

Having a loved one diagnosed with cancer can be a very difficult time for that person and those within their immediate circle. It is often difficult to know how to support the patient during their treatment and some people make mistakes in their bid to be supportive. We discuss some suggestions that could be helpful if a loved one is undergoing cancer treatment.

Nutriband (NASDAQ: NTRB), a developer of prescription transdermal pharmaceutical products, announced that its subsidiary 4P Therapeutics has signed an agreement with Brand Institute, Inc., a global leader in pharmaceutical brand name and identity development, to create the worldwide commercial brand name and visual identity for AVERSA FENTANYL, the company’s lead product utilizing its AVERSA(TM) abuse-deterrent transdermal technology. Designed to deter misuse and reduce accidental opioid exposure, AVERSA FENTANYL could become the world’s first abuse-deterrent opioid patch. Brand Institute, with a 75% share of global drug name approvals and 87% of FDA-approved names in 2024, will lead the initiative alongside its regulatory subsidiary, Drug Safety Institute, which is staffed by former FDA, EMA, Health Canada, USAN, and WHO officials.

Cutaneous T-cell lymphoma (“CTCL”) is a rare but serious form of non-Hodgkin lymphoma that primarily affects the skin. Globally, millions suffer from CTCL, and in Europe, the annual incidence is estimated at 2.9 to 3.9 cases per million people ( https://ibn.fm/ANk8X ). Despite its rarity, CTCL presents a substantial unmet medical need, particularly in early-stage patients who often have limited treatment options. Addressing this gap, Soligenix (NASDAQ: SNGX) recently announced the expansion of its European Medical Advisory Board (“MAB”) ( https://ibn.fm/6354Y ) to provide additional clinical and strategic guidance as the company advances its confirmatory phase 3 study (referred to as FLASH2) evaluating the safety and efficacy of its proprietary CTCL treatment: HyBryte(TM).

For long, treatment approaches to glioblastoma, the deadliest form of brain cancer, have assumed that the disease is localized. However, a recent study has found that GBM erodes the skulls of its victims and this could partially explain why the current therapies have had dismal success rates against the tumors.

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company developing therapies for neurodegenerative diseases including Alzheimer’s and Parkinson’s, announced new results showing that buntanetap reduced key inflammatory biomarkers and improved neuronal integrity in Alzheimer’s patients. Data from the Phase 2/3 study demonstrated lower levels of IL-5, IL-6, S100A12, IFN-γ, and IGF1R in treated patients versus placebo, along with reduced neurofilament light chain (NFL), suggesting improved cellular health and potential disease-modifying effects. CEO Maria Maccechini said the findings confirm buntanetap’s multi-targeted mechanism and validate earlier preclinical and clinical results, advancing confidence in its potential to deliver meaningful therapeutic benefit.

Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a leading medical device firm in the field of breast cancer imaging solutions, is speeding up its efforts towards commercializing its innovations. Izotropic recently made public significant progress in its IzoView Breast CT system, a feature designed to give patients a customized radiation dose ideal for their composition and breast sizes ( ibn.fm/N83Cp ).

Oncotelic Therapeutics (OTCQB: OTLC) is a clinical-stage biopharmaceutical company advancing a diversified pipeline spanning oncology, immunotherapy, neurodegeneration, and rare diseases. In a recent interview on the BioMedWire podcast, Chairman and CEO Dr. Vuong Trieu emphasized the company’s unique model: focusing on de-risked, late-stage assets and accelerating their development through regulatory pathways designed for speed and efficiency.

Nutriband (NASDAQ: NTRB) announced that Chairman Serguei Melnik will present at Noble Capital Markets’ Emerging Growth Virtual Equity Conference on Wednesday, Oct. 8, 2025, at 3 p.m. ET. The presentation will include a fireside Q&A session with questions from the live virtual audience, and registered investors can also schedule one-on-one meetings with Melnik. Interested attendees can register at no cost via the conference’s official site. A video webcast of the presentation will be available on Channelchek, Noble’s investor portal, and archived for 90 days on both Channelchek.com and Nutriband’s website.

While immunotherapy has scored a significant level of success in treating many types of cancer, it hasn’t registered similar efficacy in leukemia, especially acute myeloid leukemia, also known as AML. Researchers at Lund University, Sweden have found a possible reason why this could be so.

Lawmakers in the U.S. Congress hit a stalemate in talks to keep the government open and on Wednesday, a shutdown commenced. At the core of the disagreement between GOP lawmakers and their Democratic Party counterparts are the health care tax credits in the Affordable Care Act due to expire at the end of this year and which the Big Beautiful Bill’s provisions don’t include an extension to these tax credits.

In 2013, former CDC director Tom Frieden observed that there were rising cases of ‘nightmare bacteria’, a category of bacteria characterized by three deadly attributes; resistance to all or almost all antibiotics, high mortality levels, and their ability to spread antibiotic resistance to other types of bacteria. From this triple threat of these microbes, one can understand why they are described as ‘nightmare bacteria.’ Data shows that cases of these bacteria are increasing at an alarming rate in the U.S.

Sapu Nano, part of a group of companies formed through GMP Biotechnology Limited, which is a joint venture between Oncotelic Therapeutics (OTCQB: OTLC) and Dragon Overseas Capital Limited, recently received approval from the HREC in Australia to begin enrolling people in clinical trails of Sapu003 for the treatment of breast cancer.

Hoth Therapeutics (NASDAQ: HOTH), a biopharmaceutical company, recently announced that the company is using an AI-powered platform developed by Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotech company and pharma, to streamline and improve the drug development process ( https://ibn.fm/VIL67 ).

The sight of a scorpion moving towards you with its stinger raised can send a chill down the spine of the bravest among us. If you watched Fear Factor, you saw how terrified the contestants were to come face to face with these creatures. While scorpions have been portrayed as the stuff of nightmares, scientists have found that they can be useful in the fight against brain cancer .

On September 27, the World New Energy Vehicle Development Organization (WNEVDO) was officially established.

Psoriasis remains a persistent challenge for millions of patients worldwide, and promising new treatments are being closely watched by the medical and investor communities alike. Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on rare diseases and inflammatory conditions, is advancing its treatment candidate, SGX302, in a phase 2a clinical trial for mild-to-moderate psoriasis. The company has already seen encouraging signals in earlier proof-of-concept work, and with its current study underway, Soligenix is positioning itself to expand its presence in dermatology with a novel therapeutic option for one of the most prevalent autoimmune skin conditions.

Munich, Bavaria, Germany, September 29, 2025 -- On September 11-12, 2025, the 2nd Europe-China New Energy Vehicle Technology Conference was held in Munich, Germany. Dr. Richard Zhang, Managing Director of EVE Germany, attended and delivered a keynote speech titled "Rooted in Europe, Symbiosis and Growth." The speech outlined EVE Energy's business strategies in Europe and achievements in technological innovation, localized production, and sustainable development.

In medical imaging, technology often races ahead of regulation. A recent proposal from the Centers for Medicare & Medicaid Services (CMS) underscores this tension: the agency is opting not to mandate radiation dose tracking for CT scans by 2027. While the decision reflects operational challenges hospitals face in meeting such requirements, it also highlights a growing consensus: patients, providers, and regulators all want sharper images with lower radiation exposure.

Groundbreaking research presented at the ECTRIMS 2025 conference held in Barcelona, Spain provides new insights into the ways in which menopause impacts the health implications and clinical manifestations in women who have multiple sclerosis. This study shows that changes in hormones influence the initial symptoms experienced by women with MS and also play a role in the comorbidities suffered by the affected individuals.

When drivers think about extended car warranties, the first question that usually comes to mind is simple: How much does it cost?